SNX-482 (ammonium salt)
目录号 : GC91867SNX-482 is a peptide originally isolated from H. gigas venom that acts as a class E/R-type voltage-sensitive calcium channel blocker (IC50 = 30 nM in 192C cells expressing human class E channels).
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
SNX-482 is a peptide originally isolated from H. gigas venom that acts as a class E/R-type voltage-sensitive calcium channel blocker (IC50 = 30 nM in 192C cells expressing human class E channels).[1] It is selective for class E/R-type over class A and class B calcium channels (IC50s = >280 and ~800 nM, respectively), as well as the voltage-gated potassium channels Kv1.1, Kv1.2, and Kv1.4 (IC50s = >140 nM for all). SNX-482 inhibits class E/R-type calcium currents in isolated rat posterior pituitary (IC50 = 4 nM), however, it has no effect on class E/R-type calcium currents in isolated rat granule cells, retinal ganglion cells, or hippocampal pyramidal cells at concentrations up to 200 nM. Intrathecal administration of SNX-482 (0.5 µg/animal) inhibits formalin-induced neurokinin-1 (NK1) receptor internalization and cfos expression in the ipsilateral dorsal horn and reduces formalin-induced paw flinching in rats.[2]
References:
[1].Newcomb, R., Chen, X., Dean, R., et al.SNX‐482: A novel class E calcium channel antagonist from tarantula venomCNS Drug Rev.6(2)153-173(2000).
[2].Terashima, T., Xu, Q., Yamaguchi, S., et al.Intrathecal P/Q- and R-type calcium channel blockade of spinal substance P release and c-Fos expressionNeuropharmacology751-8(2013).
| Cas No. | N/A | SDF | Download SDF |
| 分子式 | C192H274N52O60S7•XNH4 | 分子量 | 4495 |
| 溶解度 | Water: soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2225 mL | 1.1123 mL | 2.2247 mL |
| 5 mM | 0.0445 mL | 0.2225 mL | 0.4449 mL |
| 10 mM | 0.0222 mL | 0.1112 mL | 0.2225 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。